

**FORM 3****UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES****OMB APPROVAL**

OMB Number: 3235-0104  
 Estimated average burden  
 hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
 or Section 30(h) of the Investment Company Act of 1940

<b>1. Name and Address of Reporting Person *</b> <u>Miser James</u>  (Last) (First) (Middle) <u>680 E. COLORADO BOULEVARD, SUITE 180</u>  (Street) <u>PASADENA CA 91101</u>  (City) (State) (Zip)	<b>2. Date of Event Requiring Statement (Month/Day/Year)</b> <u>08/01/2020</u>	<b>3. Issuer Name and Ticker or Trading Symbol</b> <u>LIXTE BIOTECHNOLOGY HOLDINGS, INC. [ LIXT ]</u>  <b>4. Relationship of Reporting Person(s) to Issuer</b> (Check all applicable) <div style="display: flex; justify-content: space-between;"> <div>           Director   <input checked="" type="checkbox"/> Officer (give title below)  <u>Chief Medical Officer</u> </div> <div>           10% Owner             Other (specify below)         </div> </div>	
		<b>5. If Amendment, Date of Original Filed (Month/Day/Year)</b>  <b>6. Individual or Joint/Group Filing (Check Applicable Line)</b> <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

**Table II - Derivative Securities Beneficially Owned**  
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Options to Purchase Common Stock</u>	<u>08/01/2020</u>	<u>08/01/2025</u>	<u>Common Stock</u>	<u>83,334</u>	<u>7.14</u>	<u>D</u>	

**Explanation of Responses:****Remarks:**

On August 1, 2020, the Reporting Person was granted five-year options to purchase an aggregate of 83,334 (post-split) shares of the Company's Common Stock vesting 20,833 shares on the date of grant and 25% on the first anniversary of the grant date, 25% on the second anniversary of the grant date, and 25% on the third anniversary of the grant date until fully vested.

/s/ James Miser08/01/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.